These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8687280)

  • 1. Synthesis and smooth muscle calcium channel antagonist effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrooxy or nitrophenyl moiety in the 3-alkyl ester substituent.
    Iqbal N; Knaus EE
    Arch Pharm (Weinheim); 1996 Jan; 329(1):23-6. PubMed ID: 8687280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3, 5-pyridinedicarboxylates.
    Miri R; Niknahad H; Vesal G; Shafiee A
    Farmaco; 2002 Feb; 57(2):123-8. PubMed ID: 11902654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and smooth muscle calcium channel effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrone moiety in the 4-aryl substituent.
    Anana RD; Ng H; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Mar; 330(3):53-8. PubMed ID: 9167447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers.
    Vo D; Matowe WC; Ramesh M; Iqbal N; Wolowyk MW; Howlett SE; Knaus EE
    J Med Chem; 1995 Jul; 38(15):2851-9. PubMed ID: 7543577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and smooth muscle calcium channel antagonist effects of alkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-5-[2-(4,5-dihydro- 4,4-dimethyloxazolin-2-yl)]-3-pyridinecarboxylates.
    Anana RD; Knaus EE
    Arch Pharm (Weinheim); 1996; 329(8-9):408-12. PubMed ID: 8915102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses, calcium channel antagonist and anticonvulsant activities of substituted 1,4-dihydro-3,5-pyridinedicarboxylates containing various 3-alkyl ester substituents.
    Yiu SH; Knaus EE
    Arch Pharm (Weinheim); 1997; 330(1-2):35-43. PubMed ID: 9112813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates.
    Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Wynn H; Triggle CR; Knaus EE
    J Med Chem; 1986 Dec; 29(12):2524-9. PubMed ID: 3783612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates.
    Iqbal N; Akula MR; Vo D; Matowe WC; McEwen CA; Wolowyk MW; Knaus EE
    J Med Chem; 1998 May; 41(11):1827-37. PubMed ID: 9599233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and calcium channel modulating effects of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(thienyl)-5-pyridinecarboxylates.
    Miri R; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Oct; 330(9-10):290-4. PubMed ID: 9396387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of pharmacological activities of 3, 5-dialkyl 1, 4-dihydro-2,6-dimethyl-4-nitroimidazole-3, 5-pyridine dicarboxylates.
    Miri R; Javidnia K; Kebriaie-Zadeh A; Niknahad H; Shaygani N; Semnanian S; Shafiee A
    Arch Pharm (Weinheim); 2003 Sep; 336(9):422-8. PubMed ID: 14528490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers.
    Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE
    J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro- 2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers.
    Shan R; Howlett SE; Knaus EE
    J Med Chem; 2002 Feb; 45(4):955-61. PubMed ID: 11831908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers.
    Shan R; Velazquez C; Knaus EE
    J Med Chem; 2004 Jan; 47(1):254-61. PubMed ID: 14695839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of alkyl 7,7-dihalo-3-methyl-5-(nitrophenyl)-2-azabicyclo[4.1.0]hept-3-ene-4-carboxylates with calcium channel antagonist activity.
    Mojarrad JS; Vo D; Velázquez C; Knaus EE
    Bioorg Med Chem; 2005 Jun; 13(12):4085-91. PubMed ID: 15911322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structure-activity relationships and nitric oxide release.
    Nguyen JT; Velázquez CA; Knaus EE
    Bioorg Med Chem; 2005 Mar; 13(5):1725-38. PubMed ID: 15698790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4-(pyridyl)-3,5-pyridinedicarboxylates.
    Akula MR; Matowe WC; Wolowyk MW; Knaus EE
    Pharm Res; 1990 Sep; 7(9):919-22. PubMed ID: 2235890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 1-oxido-2-pyridyl in place of the 2-nitrophenyl moiety.
    Ramesh M; Matowe WC; Wolowyk MW; Knaus EE
    Drug Des Deliv; 1988 Dec; 3(4):337-41. PubMed ID: 3255335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[3-(1-methoxy-carbonyl-4-substituted-1,4- dihydro-pyridyl)]-3,5-pyridinedicarboxylates.
    Ramesh M; Matowe WC; Knaus EE; Wolowyk MW
    Drug Des Discov; 1992 Jul; 8(4):313-23. PubMed ID: 1445996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[4-(1-methoxycarbonyl-1,4-dihydropyridyl)]-3 ,5- pyridinedicarboxylates.
    Ramesh M; Matowe WC; Wolowyk MW; Knaus EE
    Arch Pharm (Weinheim); 1999 Nov; 332(11):385-8. PubMed ID: 10605379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates.
    Dagnino L; Li-Kwong-Ken MC; Wynn H; Wolowyk MW; Triggle CR; Knaus EE
    J Med Chem; 1987 Apr; 30(4):640-6. PubMed ID: 3560157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.